Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Chemokine-modulating infusion for patients with recurrent breast cancer

Pawel Kalinski, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses promising findings of a Phase I clinical trial (NCT03599453), which assessed a chemokine-modulating infusion in patients with triple-negative breast cancer. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.